Brought to you by 
Frontier gets worldwide rights to Rockefeller U.'s 3BNC117 for use in combo HIV therapy
25 Jul 2017
Executive Summary
Frontier Biotechnologies Inc. received global rights to combine Rockefeller University's broad-spectrum HIV-neutralizing antibody 3BNC117 with its own albuvirtide for the treatment and prophylaxis of HIV and AIDS.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Frontier gets worldwide rights to Rockefeller U.'s 3BNC117 for use in combo HIV therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice